| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of D-myo-Inositol-1,4,5-triphosphate is the inositol 1,4,5-trisphosphate receptor (IP3R), a calcium channel located on the endoplasmic reticulum membrane. As a second messenger, IP3 binds to IP3 receptors, triggering the release of calcium ions from intracellular stores. This calcium release plays a crucial role in numerous cellular signaling processes including muscle contraction, neurotransmitter release, cell proliferation, and apoptosis. The compound is a key component of the phosphoinositide signaling pathway.
|
|---|---|
| ln Vitro |
An inositol phosphate derivative is second messenger D-myo-Inositol 1,4,5-trisphosphate (1,4,5-IP3). When Pr55Gag is complexed with D-myo-Inositol 1,4, 5-trisphosphate—an inositol lacking lipid groups and containing divalent phosphate groups—the dissociation constant (KD) is 2170 μM. D-myo-Inositol 1,4,5-trisphosphate (KD=568 μM) and 1,3,4,5-IP4 (KD=526 μM) have nearly equal binding affinities for matrix (MA)[1].
D-myo-Inositol-1,4,5-triphosphate acts as a second messenger in cellular signaling. It binds to inositol 1,4,5-trisphosphate receptors (IP3Rs) on the endoplasmic reticulum, stimulating the release of calcium ions from intracellular stores. This calcium mobilization triggers a cascade of downstream signaling events. The compound is produced in cells by phospholipase C-mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP₂) in response to various extracellular stimuli including hormones, neurotransmitters, and growth factors. |
| ln Vivo |
In vivo, D-myo-Inositol-1,4,5-triphosphate functions as a second messenger in cellular signaling. It is produced in response to extracellular stimuli and triggers the release of calcium ions from the endoplasmic reticulum, which regulates numerous physiological processes. The compound is not used as a therapeutic agent but is a fundamental signaling molecule in all eukaryotic cells. It plays essential roles in cellular processes including muscle contraction, neurotransmitter release, cell proliferation, and apoptosis.
|
| Enzyme Assay |
In vitro receptor binding assays for D-myo-Inositol-1,4,5-triphosphate typically involve measuring its binding to IP3 receptors (IP3Rs) using radioligand binding techniques. Radiolabeled IP3 ([³H]IP3) is incubated with membrane preparations containing IP3Rs in the presence of varying concentrations of unlabeled IP3, and specific binding is determined. Calcium release assays can be performed using permeabilized cells or microsomal preparations loaded with fluorescent calcium indicators (such as Fura-2 or Fluo-4) to measure IP3-induced calcium mobilization. The compound's purity is confirmed by HPLC.
|
| Cell Assay |
In vitro cellular assays for D-myo-Inositol-1,4,5-triphosphate typically involve loading cells with fluorescent calcium indicators (such as Fura-2, Fluo-4, or Indo-1) and measuring intracellular calcium changes in response to IP3 or IP3-generating stimuli. Permeabilized cells or patch-clamp techniques can be used to directly apply IP3 to the intracellular environment. Calcium release from the endoplasmic reticulum is measured by fluorescence microscopy or fluorometry. The compound is a second messenger that plays a crucial role in cellular signaling.
|
| Animal Protocol |
In vivo animal experiments are not typically performed with D-myo-Inositol-1,4,5-triphosphate as a direct pharmacological agent, as it is an intracellular second messenger that does not cross cell membranes effectively. However, studies may involve the use of membrane-permeable analogs or caged IP3 compounds that can be photolyzed to release IP3 inside cells. The compound is used in ex vivo studies with isolated tissues or cells to study calcium signaling pathways.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of D-myo-Inositol-1,4,5-triphosphate are not applicable in the traditional sense, as it is an intracellular second messenger rather than a therapeutic agent. The compound has a molecular weight of 486.04 g/mol and a molecular formula of C₆H₁₂Na₃O₁₅P₃. As a highly polar phosphorylated compound, it does not readily cross cell membranes. The compound is used as a reagent in biochemical and cell biology research to study calcium signaling pathways.
|
| Toxicity/Toxicokinetics |
The toxicological profile of D-myo-Inositol-1,4,5-triphosphate is not extensively documented, as it is a naturally occurring second messenger used as a research reagent rather than a therapeutic agent. As an endogenous signaling molecule, it is not expected to be toxic at physiological concentrations. However, standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Anraku K, et al. Highly sensitive analysis of the interaction between HIV-1 Gag and phosphoinositide derivatives based on surface plasmon resonance. Biochemistry. 2010 Jun 29;49(25):5109-16.
|
| Additional Infomation |
Inositol 1,4,5-trisphosphate trisodium (CAS# 141611-10-1, molecular formula C₆H₁₂Na₃O₁₅P₃, molecular weight 486.04) is a second messenger that binds to IP3 receptors and stimulates calcium release from the endoplasmic reticulum. Also known as Ins(1,4,5)-P3 trisodium. No clinical trials or regulatory approvals have been identified.
|
| Molecular Formula |
C6H12NA3O15P3
|
|---|---|
| Molecular Weight |
486.04
|
| Exact Mass |
485.908
|
| CAS # |
141611-10-1
|
| Related CAS # |
D-myo-Inositol 1,4,5-trisphosphate hexapotassium salt;103476-24-0
|
| PubChem CID |
16760520
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
605
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
O([C@@H]1[C@H]([C@H](OP(O)(O)=O)[C@H](O)[C@H](O)[C@H]1OP(O)(O)=O)O)P(O)(O)=O.[NaH]
|
| InChi Key |
ZVCVTWVBDIPWPZ-ZKVWPJASSA-K
|
| InChi Code |
InChI=1S/C6H15O15P3.3Na/c7-1-2(8)5(20-23(13,14)15)6(21-24(16,17)18)3(9)4(1)19-22(10,11)12;;;/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18);;;/q;3*+1/p-3/t1-,2+,3+,4-,5-,6-;;;/m1.../s1
|
| Chemical Name |
trisodium;[(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-bis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0574 mL | 10.2872 mL | 20.5744 mL | |
| 5 mM | 0.4115 mL | 2.0574 mL | 4.1149 mL | |
| 10 mM | 0.2057 mL | 1.0287 mL | 2.0574 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
